[1] HEIT J J，WINTERMARK M. Imaging selection for

reperfusion therapy in acute ischemic stroke[J]. Curr

Treat Options Neurol，2015，17（2）：332.

[2] MENON B K，D'ESTERRE C D，QAZI E M，et

al. Multiphase CT angiography：a new tool for the

imaging triage of patients with acute ischemic

stroke[J]. Radiology，2015，275（2）：510-520.

[3] HOPYAN J，CIARALLO A，DOWLATSHAHI

D，et al. Certainty of stroke diagnosis：incremental

benefit with CT perfusion over non-contrast CT and

CT angiography[J]. Radiology，2010，255（1）：142-

153.

[4] TAN MY，SINGHAL S，MA H，et al. Examining

subcortical infarcts in the era of acute multimodality

CT Imaging[J]. Front Neurol，2016，7（3）：220.

[5] MILES K A，HAYBALL M P，DIXON A K.

Functional images of hepatic perfusion obtained with

dynamic CT[J]. Radiology，1993，188（2）：405-411.

[6] PEPPER E M，PARSONS M W，BATEMAN G

A，et al. CT perfusion source images improve

identification of early ischaemic change in

hyperacute stroke[J]. J Clin Neurosci，2006，13（2）：

199-205.

[7] KOENIG M，KRAUS M，THEEK C，et al.

Quantitative assessment of the ischemic brain by

means of perfusion-related parameters derived from

perfusion CT[J]. Stroke，2001，32（2）：431-437.

[8] CAMPBELL B C，WEIR L，DESMOND P M，et

al. CT perfusion improves diagnostic accuracy and

confidence in acute ischaemic stroke[J]. J Neurol

Neurosurg Psychiatry，2013，84（6）：613-618.

[9] TSOGKAS I，KNAUTH M，SCHREGEL K，et

al. Added value of CT perfusion compared to CT

angiography in predicting clinical outcomes of stroke

patients treated with mechanical thrombectomy[J].

Eur Radiol，2016，26（11）：4213-4219.

[10] DOUCET C，RONCAROLO F，TAMPIERI D，et

al. Paradoxically decreased mean transit time in

patients presenting with acute stroke[J]. J Comput

Assist Tomogr，2016，40（3）：409-412.

[11] BENNINK E，RIORDAN A J，HORSCH A D，et

al. A fast nonlinear regression method for estimating

permeability in CT perfusion imaging[J]. J Cereb

Blood Flow Metab，2013，33（11）：1743-1751.

[12] LEIGH R，CHRISTENSEN S，CAMPBELL B C，

et al. Pretreatment blood-brain barrier disruption

and post-endovascular intracranial hemorrhage[J].

Neurology，2016，87（3）：263-269.

[13] GAO T，ZHANG Z，YU W，et al. Atherosclerotic

carotid vulnerable plaque and subsequent stroke：a

high-resolution MRI study[J]. Cerebrovasc Dis，

2009，27（4）：345-352.

[14] UNDERHILL H R，HATSUKAMI T S，CAI J，et

al. A noninvasive imaging approach to assess plaque

severity：the carotid atherosclerosis score[J]. AJNR

Am J Neuroradiol，2010，31（6）：1068-1075.

[15] WASSERMAN B A. Advanced contrast-enhanced

MRI for looking beyond the lumen to predict stroke：

building a risk profile for carotid plaque[J]. Stroke，

2010，41（10 Suppl）：S12-16.

[16] U-KING-IM J M，TANG T Y，PATTERSON

A，et al. Characterisation of carotid atheroma in

symptomatic and asymptomatic patients using high

resolution MRI[J]. J Neurol Neurosurg Psychiatry，

2008，79（8）：905-912.

[17] TAKAYA N，YUAN C，CHU B，et al. Association

between carotid plaque characteristics and

subsequent ischemic cerebrovascular events：a

prospective assessment with MRI--initial results[J].

Stroke，2006，37（3）：818-823.

[18] DIELEMAN N，VAN DER KOLK A G，

ZWANENBURG J J，et al. Imaging intracranial

vessel wall pathology with magnetic resonance

imaging：current prospects and future directions[J].

Circulation，2014，130（2）：192-201.

[19] JIA D M，CHEN Z B，ZHANG M J，et al. CYP2C19

polymorphisms and antiplatelet effects of clopidogrel

in acute ischemic stroke in China[J]. Stroke，2013，

44（6）：1717-1719.

[20] LIN Y J，LI J W，ZHANG M J，et al. The

association between CYP2C19 Genotype and of instent

restenosis among patients with vertebral artery

stent treatment[J]. CNS Neurosci Ther，2014，20（2）：

125-130.

[21] PAN Y，CHEN W，XU Y，et al. Genetic

polymorphisms and clopidogrel efficacy for acute

ischemic stroke or transient ischemic attack：a

systematic review and meta-analysis[J]. Circulation，

2017，135（1）：21-33.

[22] AMARENCO P，ALBERS G W，DENISON

H，et al. Efficacy and safety of ticagrelor versus

aspirin in acute stroke or transient ischaemic attack

of atherosclerotic origin：a subgroup analysis

of SOCRATES，a randomised，double-blind，

controlled trial[J]. Lancet Neurol，2017，16(4):301-

310.